First Manhattan’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

First Manhattan’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3	Closed	-$219	–	1383
2024 Q1	$219	Hold	3	–	–	﹤0.01%	1374
2023 Q4	$517	Hold	3	–	–	﹤0.01%	1362
2023 Q3	$2.06K	Hold	3	–	–	﹤0.01%	1312
2023 Q2	$13.4K	Hold	3	–	–	﹤0.01%	1090
2023 Q1	$7.72K	Sell	3 -1	-25%	-$2.93K	﹤0.01%	1242
2022 Q4	$9.62K	Hold	4	–	–	﹤0.01%	1255
2022 Q3	$14K	Sell	4 -3	-43%	-$11.8K	﹤0.01%	1155
2022 Q2	$16K	Buy	7 +1	+17%	+$2.6K	﹤0.01%	1157
2022 Q1	$18K	Hold	6	–	–	﹤0.01%	1184
2021 Q4	$35K	Hold	6	–	–	﹤0.01%	1066
2021 Q3	$52K	Hold	6	–	–	﹤0.01%	987
2021 Q2	$57K	Buy	6 +3	+100%	+$49.3K	﹤0.01%	957
2021 Q1	$60K	Buy	+3	New	+$35K	﹤0.01%	927

Other funds holding SEEL

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CHA

Carmichael Hill & Associates Gaithersburg, Maryland $282M AUM 32.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

First Manhattan's SEEL Position: Q2 2024 in Review

First Manhattan sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2024, closing a stake of 3 shares — an estimated $219 sold.

First Manhattan first reported a position in SEEL in Q1 2021 and held it in 13 quarters. The position peaked at $60K in Q1 2021. 18 funds tracked by Wall St. Rank hold SEEL as of Q2 2024.

First Manhattan reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 3 Seelos Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $219.
First Manhattan first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
First Manhattan's Seelos Therapeutics, Inc. Common Stock position peaked at $60K in Q1 2021.
18 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.